CD206 Modulators and Their Uses and Preparation Methods
By activate the M1-like phenotype by small molecule regulators targeting the CD206 receptor, the problem of M2 macrophages supporting tumor growth in cancers such as pancreatic cancer is solved, and tumor suppression and survival rates are improved.
CN115768757BActive Publication Date: 2025-07-11THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
3 Cites 0 Cited by
Patent Information
- Application Number
- CN202080096478.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-19
- Filing Date
- 2020-12-16
- Publication Date
- 2025-07-11
- Estimated Expiration
- 2040-12-16
AI Technical Summary
Technical Problem
The prior art is difficult to effectively regulate the CD206 receptor, resulting in poor immunotherapy for solid organ cancer such as pancreatic cancer. Tumor cells support tumor growth and metastasis by attracting and reprogramming natural immune cells.
Method used
Develop small molecule regulators targeting the CD206 receptor, which activates the M1-like phenotype, kills or reprograms M2 macrophages, alters the tumor microenvironment and enhances the immune response by binding to the CD206 receptor.
Benefits of technology
Significantly inhibit tumor growth, improve the therapeutic effect of cancers such as pancreatic cancer, improve patient survival rate, and reduce tumor volume and weight.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to compounds of Formula I, Formula II, and Formula III, and pharmaceutically acceptable salts thereof. Variables X, a, b, c, d, R 1‑4 , R 10‑15 and R 17‑22 are disclosed. These compounds can be used for treating cancer disorders, particularly those involving the M2 phenotype of macrophages. Pharmaceutical compositions comprising a compound of Formula I or Formula II or Formula III, and methods of treatment, which include administering compounds of Formula I, Formula II, and Formula III, are also disclosed.
Need to check novelty before this filing date? Find Prior Art